Document Detail


Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens.
MedLine Citation:
PMID:  17700384     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An estimated 71 million individuals in the United States are currently diagnosed with cardiovascular disease (CVD). If untreated, CVD conditions such as systemic hypertension, coronary artery disease, and heart failure will have potentially serious and often fatal outcomes. Numerous clinical trials have established a variety of evidence-based medications that are efficacious in the treatment of CVD. These drugs will be ineffective, however, if patients have trouble adhering to their prescribed regimens. In patients with hypertension or heart failure, or in those who have suffered a myocardial infarction, poor adherence to therapies has been linked to a variety of problems, including poor blood pressure control, rehospitalization, and increased healthcare resource utilization. Both the asymptomatic nature of some forms of CVD and the high pill burden associated with certain therapies have been linked to poor adherence. Reducing pill burden through the use of once-daily formulations has proven valuable in improving adherence to evidence-based therapies. This review will discuss the impact of adherence to prescribed therapies for CVD, outline common barriers to adherence, and demonstrate the value of once-daily dosing regimens for improved patient adherence.
Authors:
William H Frishman
Related Documents :
12691644 - Nonpharmacologic options for the management of heart failure.
20588214 - Emerging role of nuclear cardiology in heart failure.
19219554 - Myocardial adaptations in the failing heart: cause or consequence?
8074594 - Diuretic treatment for the sodium retention of congestive heart failure.
17951624 - Prognostic value of echocardiographic right/left ventricular end-diastolic diameter rat...
11216744 - Coronary artery fistulas: long-term results of surgical correction.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiology in review     Volume:  15     ISSN:  1538-4683     ISO Abbreviation:  Cardiol Rev     Publication Date:    2007 Sep-Oct
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-09-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9304686     Medline TA:  Cardiol Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  257-63     Citation Subset:  IM    
Affiliation:
Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA. william_frishman@nymc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / administration & dosage
Cardiovascular Diseases / drug therapy*
Chronic Disease
Delayed-Action Preparations
Drug Administration Schedule
Drug Therapy, Combination
Heart Failure / drug therapy,  prevention & control
Humans
Hypertension / drug therapy,  prevention & control
Myocardial Infarction / drug therapy,  prevention & control
Patient Compliance* / psychology,  statistics & numerical data
Patient Readmission / statistics & numerical data
Recurrence / prevention & control
Tablets
Treatment Refusal / psychology,  statistics & numerical data*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Delayed-Action Preparations; 0/Tablets

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Next Document:  Sitagliptin: a novel drug for the treatment of type 2 diabetes.